Halozyme Therapeutics, Inc.
A San Diego biopharma company whose ENHANZE technology uses a naturally occurring enzyme to temporarily loosen the gel-like tissue under the skin, letting large-volume biologic medicines be injected in minutes instead of slowly dripped over hours. Its partners sell drugs built on this platform, such as DARZALEX FASPRO and HYQVIA, and it also makes auto-injector devices and its own products like XYOSTED. Co-founded in 1998 by Dr. Gregory Frost, the company's name blends "hyaluronidase" and "enzyme" — the very molecule its science revolves around.
Granted 212.4K · Bought 14.53M · Sold 3.51M
Granted 1.23M · Bought 8.0K · Sold 443.4K
Granted 2.97M · Bought 50.0K · Sold 1.54M
Granted 535.5K · Sold 415.0K
Granted 271.9K · Bought 35.0K · Sold 30.0K
Granted 208.3K · Bought 150.0K
Granted 394.9K · Bought 30.0K · Sold 186.7K
Granted 359.9K · Sold 512.5K
Granted 289.8K · Sold 64.0K
Granted 503.8K · Bought 92.6K · Sold 416.5K
Granted 665.2K · Sold 567.7K
Granted 181.0K · Bought 10.0K
Granted 95.8K · Sold 29.9K
Granted 157.7K · Sold 79.9K
Granted 101.8K · Sold 35.0K
Granted 104.3K
Granted 27.7K · Bought 20.0K
Granted 103.7K
Granted 55.0K
Granted 63.7K · Sold 14.1K
Granted 149.8K · Sold 64.8K
Granted 14.8K · Sold 3.9K
Granted 106.1K · Sold 69.5K
Granted 27.7K · Bought 8.0K
Granted 80.0K · Sold 50.0K
Granted 24.9K
Granted 23.7K
Granted 20.9K
Granted 85.2K · Sold 64.7K
Granted 20.2K
Granted 28.3K
Granted 33.5K · Sold 33.1K
Granted 21.8K · Sold 7.3K
Granted 22.4K
Granted 23.2K · Sold 10.0K
Bought 13.0K
Granted 4.7K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Kirk Randal J10% owner · 160 transactions | — | 14.09Mas of Aug 2018 | 212.4K | 14.53M | 3.51M |
| Frost Gregory IanCEO, President, Director · 327 transactions | — | 3.64Mas of Dec 2013 | 1.23M | 8.0K | 443.4K |
| Torley HelenPRESIDENT AND CEO, Director · 335 transactions | — | 773.9K | 2.97M | 50.0K | 1.54M |
| Lim Jonathan EChief Executive Officer, Director · 218 transactions | — | 710.0Kas of Jan 2010 | 535.5K | — | 415.0K |
| Ramsay David AVP and Chief Financial Officer · 55 transactions | — | 367.0Kas of Feb 2015 | 271.9K | 35.0K | 30.0K |
| Falberg Kathryn EDirector · 15 transactions | — | 358.3Kas of May 2016 | 208.3K | 150.0K | — |
| Engler RobertDirector · 22 transactions | — | 308.2Kas of Aug 2014 | 394.9K | 30.0K | 186.7K |
| Patton John StuartDirector · 378 transactions | — | 254.9Kas of Aug 2014 | 359.9K | — | 512.5K |
| Matsui ConnieDirector · 29 transactions | — | 183.0Kas of Nov 2024 | 289.8K | — | 64.0K |
| Kelley Kenneth JDirector · 256 transactions | — | 179.8Kas of Apr 2021 | 503.8K | 92.6K | 416.5K |
| LaBarre Michael J.SVP, CHIEF TECHNICAL OFFICER · 168 transactions | — | 173.8Kas of Feb 2025 | 665.2K | — | 567.7K |
| Stelzer LaurieSVP, Chief Financial Officer · 28 transactions | — | 130.7Kas of Feb 2020 | 181.0K | 10.0K | — |
| Yocum Richard CVP Clinical Development · 10 transactions | — | 87.0Kas of Mar 2007 | 95.8K | — | 29.9K |
| Posard Matthew L.Director · 22 transactions | — | 77.8K | 157.7K | — | 79.9K |
| Bizzari Jean-PierreDirector · 11 transactions | — | 66.8Kas of May 2023 | 101.8K | — | 35.0K |
| Leonhardt Harry JSVP, GC · 20 transactions | — | 66.4Kas of Apr 2019 | 104.3K | — | — |
| Shaffer James PVP & Chief Commercial Officer · 6 transactions | — | 54.0Kas of Feb 2014 | 27.7K | 20.0K | — |
| Snyder Mark HowardSVP, CHIEF LEGAL OFFICER · 28 transactions | — | 52.6K | 103.7K | — | — |
| Countouriotis AthenaSVP and Chief Medical Officer · 9 transactions | — | 46.0Kas of Feb 2017 | 55.0K | — | — |
| Connaughton BernadetteDirector · 20 transactions | — | 43.7K | 63.7K | — | 14.1K |
| LaBrosse NicoleSVP, CHIEF FINANCIAL OFFICER · 62 transactions | — | 42.1K | 149.8K | — | 64.8K |
| Chondros DimitriosSVP, Chief Medical Officer · 11 transactions | — | 38.6Kas of Aug 2019 | 14.8K | — | 3.9K |
| Henderson Jeffrey WilliamDirector · 23 transactions | — | 36.6K | 106.1K | — | 69.5K |
| Gustafson Kurt AVice President and CFO · 4 transactions | — | 31.7Kas of Feb 2013 | 27.7K | 8.0K | — |
| Thornton Steven TDirector · 48 transactions | — | 30.0Kas of May 2008 | 80.0K | — | 50.0K |
| Miyashita Akiko MoniDirector · 4 transactions | — | 24.9Kas of May 2025 | 24.9K | — | — |
| Duncan Barbara GayleDirector · 5 transactions | — | 23.7K | 23.7K | — | — |
| Liu Jean IVP & General Counsel · 3 transactions | — | 20.9Kas of Feb 2014 | 20.9K | — | — |
| Daly James MDirector · 12 transactions | — | 20.5Kas of Aug 2023 | 85.2K | — | 64.7K |
| Hickey BenjaminSVP, Chief Commerical Officer · 2 transactions | — | 20.2Kas of Oct 2019 | 20.2K | — | — |
| Matsuda MasaruSVP, General Counsel · 10 transactions | — | 20.0Kas of Sep 2021 | 28.3K | — | — |
| Caudill CortneySVP, CHIEF OPERATING OFFICER · 9 transactions | — | 15.9K | 33.5K | — | 33.1K |
| Krishnan MaheshDirector · 5 transactions | — | 14.5K | 21.8K | — | 7.3K |
| Sun Elaine DSVP, Chief Financial Officer · 4 transactions | — | 14.0Kas of Apr 2021 | 22.4K | — | — |
| Shepard H. MichaelVP, Chief Scientific Officer · 4 transactions | — | 13.2Kas of Aug 2013 | 23.2K | — | 10.0K |
| Little Robert JVP, Chief Commercial Officer · 7 transactions | — | 13.0Kas of Mar 2008 | — | 13.0K | — |
| Lang James PaulDirector · 2 transactions | — | 4.7K | 4.7K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: +6.80M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.